Anika Therapeutics | ANIK - Cash And Equivalent


Anika Therapeutics reported $38.41M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Agenus USD 18.74M 16.26M Jun/2026
Agios Pharmaceuticals USD 99.65M 13.95M Jun/2026
Anika Therapeutics USD 38.41M 2.61M Jun/2026
Arrowhead Research USD 19.68M 127.85M Jun/2026
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
Heron Therapeutics USD 20.72M 5.4M Jun/2026
Insmed USD 544.76M 37.42M Jun/2026
Integra LifeSciences USD 214.42M 22.39M Jun/2026
Intrexon USD 9.34M 1.77M Jun/2024
J&J USD 20.42B 1.27B Jun/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
Ligand Pharmaceuticals USD 1.01B 891.62M Jun/2026
MacroGenics USD 113.91M 47.39M Jun/2026
Merit Medical Systems USD 448.7M 39.38M Jun/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
Stryker USD 3.39B 513M Jun/2026
Veracyte USD 299.52M 36.38M Jun/2026
Xencor USD 44.66M 30.49M Jun/2026
Zimmer Biomet Holdings USD 410M 14.2M Jun/2026